US FDA Revises 'Disruptive' Generics Communications Policies
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration has unveiled a revised manual of policies and procedures (MAPP) intended to improve the communications between regulators reviewing abbreviated new drug applications (ANDAs) and the companies that have submitted them1.